Identification of a peptide that bound to human breast carcinoma cells expressing EGFL6 offered the potential that the EGFL6 peptide could be used in vivo to detect tumorigenesis in xenografts expressing the potential tumor vasculature ligand. This evidence concerns the gene EGFL6 and breast carcinoma.